Skip to contentH
Halozyme Therapeutics, Inc.
H
HALOHalozyme Therapeutics, Inc. Q4 2015 · 10-K
Revenue$39.00M$39.00M+28.4% vs Q4 2014 Net Income-$27.39M-$27.39MN/M vs Q4 2014 EPS Diluted$0.03$0.03N/M vs Q4 2014 Gross Profit$5,420,000+35.6% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Halozyme Therapeutics, Inc. · CIK 1159036 · Engraved from SEC EDGAR
derived
Operating Cash Flowderived-$15,197,000N/M Free Cash Flowderived-$16,831,000N/M Margins · derivedGross margin13.9%+0.7 pt vs Q4 2014
Operating margin14.0%+26.7 pt vs Q4 2014
Net margin-70.2%−52.9 pt vs Q4 2014
ended Dec 31, 2015 · filed Feb 29, 2016 · 60 d after period end